(Albany, US) DelveInsight has launched a new report on Choroidal Neovascularization Pipeline Insight, 2020.
“Choroidal Neovascularization Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Choroidal Neovascularization market. A detailed picture of the Choroidal Neovascularization pipeline landscape is provided, which includes the disease overview and Choroidal Neovascularization treatment guidelines.
The assessment part of the report embraces in-depth Choroidal Neovascularization commercial assessment and clinical assessment of the Choroidal Neovascularization pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Choroidal Neovascularization collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Some of the key companies working on Choroidal Neovascularization are:
- AnewPharma
- Iconic Therapeutics
- Adverum Biotechnologies
- And Many Others.
The launch of the emerging therapies is expected to significantly impact the Choroidal Neovascularization treatment scenario in the upcoming years:-
Drugs Covered:
- CM082
- ICON-1
- ADVM-022
- And Many Others.
Request for Sample Pages: https://www.delveinsight.com/sample-request/choroidal-neovascularization-pipeline-insight
Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub–retinal pigment epithelium (sub-RPE) or subretinal space. CNV is a major cause of visual loss. The symptoms of CNV include a distortion or waviness of central vision or a gray/black/void spot in the central vision.
Conditions That May Cause Choroidal Neovascularization:
• Age-related macular degeneration is the most common disease causing CNV, but other diseases that “stress” the retina, causing it to produce excess VEGF, or disrupting the barrier between the retina and choroid, can also cause CNV.
• In patients with pathologic myopia (extreme nearsightedness), the eye is longer than normal, and this lengthening stretches and stresses the retina.
• Ocular histoplasmosis is a fungal infection that can cause CNV.
• Eye trauma and angioid streaks (small breaks in one of the retina’s layers) can break the barrier between the retina and choroid, resulting in CNV.
• Severe ocular inflammation, a condition called uveitis, can also cause CNV.
• The ophthalmologist can detect CNV using a combination of techniques. First, during the dilated eye exam, she/he may see a blister of fluid or bleeding in the retina. Then, using specialized imaging called optical coherence tomography (OCT), a cross-section picture of the retina is obtained. This image can detect even small amounts of fluid that have leaked into the retina from CNV.
Request for Sample Pages: https://www.delveinsight.com/sample-request/choroidal-neovascularization-pipeline-insight
Table Of Contents:
1. Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Choroidal Neovascularization Market Overview at a Glance
4.1. 7 Major Market Size of Choroidal Neovascularization in 2017
4.2. 7 Major Market Size of Choroidal Neovascularization in 2030
5. Disease Background and Overview: Choroidal Neovascularization
5.1. Introduction
5.2. Causes
5.3. Pathophysiology
5.4. Symptoms
5.5. Risk Factor
5.6. Diagnosis
6. Epidemiology and Patient Population
6.1. Assumptions and Rationale
6.2. 7MM Incident cases of Choroidal Neovascularization (2017–2030)
6.3. 7MM Cause-specific Incidence of Choroidal Neovascularization (2017–2030)
6.4. 7MM Diagnosed and Treatable Cases of Choroidal Neovascularization (2017–2030)
7. Choroidal Neovascularization: Country- Wise Epidemiology
7.1. United States
7.1.1. Incident cases of Choroidal Neovascularization in the United States (2017–2030)
7.1.2. Cause-specific Incidence of Choroidal Neovascularization (2017–2030)
7.1.3. Diagnosed and Treatable Cases of Choroidal Neovascularization in the United States (2017–2030)
7.2. EU-5
7.2.1. Germany
7.2.1.1. Incident cases of Choroidal Neovascularization in Germany (2017–2030)
7.2.1.3. Cause-specific Incidence of Choroidal Neovascularization in Germany (2017–2030)
7.2.1.3. Diagnosed and Treatable Cases of Choroidal Neovascularization in Germany (2017–2030)
7.2.2. France
7.2.2.1. Incident cases of Choroidal Neovascularization in France (2017–2030)
7.2.2.3. Cause-specific Incidence of Choroidal Neovascularization in France (2017–2030)
7.2.2.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in France (2017–2030)
7.2.3. Italy
7.2.3.1. Incident cases of Choroidal Neovascularization in Italy (2017–2030)
7.2.3.3. Cause-specific Incidence of Choroidal Neovascularization in Italy (2017–2030)
7.2.3.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in Italy (2017–2030)
7.2.4. Spain
7.2.4.1. Incident cases of Choroidal Neovascularization in Spain (2017–2030)
7.2.4.3. Cause-specific Incidence of Choroidal Neovascularization in Spain (2017–2030)
7.2.4.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in Spain (2017–2030)
7.2.5. United Kingdom
7.2.5.1. Incident cases of Choroidal Neovascularization in the United Kingdom (2017–2030)
7.2.5.3. Cause-specific Incidence of Choroidal Neovascularization in the United Kingdom (2017–2030)
7.2.5.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in the United Kingdom (2017–2030)
7.3. Japan
7.3.1. Incident cases of Choroidal Neovascularization in Japan (2017–2030)
7.3.3. Cause-specific Incidence of Choroidal Neovascularization in Japan (2017–2030)
7.3.4. Diagnosed and Treatable Cases of Choroidal Neovascularization in Japan (2017–2030)
8. Treatment & Medical Practices
8.1. Treatment Algorithm
8.2. Treatment Guidelines
9. Patient Journey
10. Marketed Drugs
10.1. Lucentis : Roche
10.1.1. Product Description
10.1.2. Regulatory Milestones
10.1.3. Advantages & Disadvantages
10.1.4. Product Profile
10.1.5. Safety and Efficacy
10.1.6. Side effects
10.2. Eylea: Regeneron Pharmaceuticals
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Advantages & Disadvantages
10.2.4. Product Profile
10.2.5. Safety and Efficacy
10.2.6. Side effects
11. Key Emerging Therapies
11.1. ADVM-022: Adverum Biotechnologies
11.1.1. Regulatory Milestones
11.1.2. Clinical Development
11.1.3. Product Profile
11.1.4. Clinical Pipeline Activity
11.1.5. Ongoing Trials Information
11.1.6. Clinical Trial by Phase
11.2. ICON-1: Iconic Therapeutics
11.2.1. Regulatory Milestones
11.2.2. Clinical Development
11.2.3. Product Profile
11.2.4. Clinical Pipeline Activity
11.2.5. Ongoing Trials Information
11.2.6. Clinical Trial by Phase
To be continued in the report………
12. Attribute Analysis
13. Choroidal Neovascularization: Market Size
13.1. Key Findings
13.2. Total 7MM Choroidal Neovascularization Market Analysis
13.2.1. Overview of Total Choroidal Neovascularization Market
13.2.2. Market size of Choroidal Neovascularization by 7MM (2017–2030)
14. 7MM Choroidal Neovascularization: Country-Wise Market Analysis
14.1. United States
14.1.1. Total Market Size of Choroidal Neovascularization
14.1.2. Market Size of Choroidal Neovascularization by Therapies
14.2. Germany
14.2.1. Total Market Size of Choroidal Neovascularization
14.2.2. Market Size of Choroidal Neovascularization by Therapies
14.3. France
14.3.1. Total Market Size of Choroidal Neovascularization
14.3.2. Market Size of Choroidal Neovascularization by Therapies
14.4. United Kingdom
14.4.1. Total Market Size of Choroidal Neovascularization
14.4.2. Market Size of Choroidal Neovascularization by Therapies
14.5. Spain
14.5.1. Total Market Size of Choroidal Neovascularization
14.5.2. Market Size of Choroidal Neovascularization by Therapies
14.6. Italy
14.6.1. Total Market Size of Choroidal Neovascularization
14.6.2. Market Size of Choroidal Neovascularization by Therapies
14.7. Japan
14.7.1. Total Market Size of Choroidal Neovascularization
14.7.2. Market Size of Choroidal Neovascularization by Therapies
15. Market Access and Reimbursement
16. Market Drivers
17. Market Barriers
18. Appendix
19. Report Methodology
19.1. Sources Used
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Related Reports:
Choroidal Neovascularization Market Insight, Epidemiology and Market Forecast -2030
The Choroidal Neovascularization market report provides current treatment practices, emerging drugs, Choroidal Neovascularization market share of the individual therapies, current and forecasted Choroidal Neovascularization market Size from 2017 to 2030 segmented by seven major markets.
Choroidal Neovascularization – Epidemiology Forecast to 2030
The Choroidal Neovascularization epidemiology covered in the report provides historical as well as forecasted Choroidal Neovascularization epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/choroidal-neovascularization-pipeline-insight